BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23559420)

  • 1. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Barocas DA; Grubb R; Black A; Penson DF; Fowke JH; Andriole G; Crawford ED
    Cancer; 2013 Jun; 119(12):2223-9. PubMed ID: 23559420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
    Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
    Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
    Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04.
    Lacher DA; Thompson TD; Hughes JP; Saraiya M
    Adv Data; 2006 Dec; (379):1-12. PubMed ID: 17348177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
    Espaldon R; Kirby KA; Fung KZ; Hoffman RM; Powell AA; Freedland SJ; Walter LC
    Urology; 2014 Mar; 83(3):599-605. PubMed ID: 24439009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
    Pinsky PF; Parnes HL; Andriole G
    BJU Int; 2014 Feb; 113(2):254-9. PubMed ID: 24053621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men.
    Lee KM; Bryant AK; Lynch JA; Robison B; Alba PR; Agiri FY; Pridgen KM; DuVall SL; Yamoah K; Garraway IP; Rose BS
    Cancer; 2024 Jan; 130(2):224-231. PubMed ID: 37927109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
    Verges DP; Dani H; Sterling WA; Weedon J; Atallah W; Mehta K; Schreiber D; Weiss JP; Karanikolas NT
    J Natl Med Assoc; 2017 Spring; 109(1):49-54. PubMed ID: 28259216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
    Smith DS; Carvalhal GF; Mager DE; Bullock AD; Catalona WJ
    J Urol; 1998 Nov; 160(5):1734-8. PubMed ID: 9783942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.
    Sammon JD; Dalela D; Abdollah F; Choueiri TK; Han PK; Hansen M; Nguyen PL; Sood A; Menon M; Trinh QD
    J Urol; 2016 Apr; 195(4 Pt 1):913-8. PubMed ID: 26598427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
    Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
    J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.
    Sterling WA; Weiner J; Schreiber D; Mehta K; Weiss JP
    Int Urol Nephrol; 2016 Dec; 48(12):2015-2021. PubMed ID: 27580731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
    Etzioni R; Berry KM; Legler JM; Shaw P
    Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
    Riviere P; Kalavacherla S; Banegas MP; Javier-Desloges J; Martinez ME; Garraway IP; Murphy JD; Rose BS
    Cancer; 2023 Jan; 129(1):82-88. PubMed ID: 36345568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in screening for prostate cancer in the elderly.
    Gilligan T; Wang PS; Levin R; Kantoff PW; Avorn J
    Arch Intern Med; 2004 Sep; 164(17):1858-64. PubMed ID: 15451760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.